Herbal Medication (Gongjin-dan) for Chronic Dizziness
Status:
Unknown status
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, randomized, double-blinded, placebo-controlled,
parallel-group, clinical trial to explore the effectiveness of an herbal medication,
Gongjin-dan (GJD) for chronic dizziness (Ménière disease, psychogenic dizziness, or dizziness
of unknown cause), identified as liver-deficiency pattern/syndrome, and assessed with
Dizziness Handicap Inventory (DHI) ≥ 24 at baseline. Participants will be randomized and
allocated to either GJD or placebo group with 1:1 ratio and orally administered GJD or
placebo pills once a day for 8 weeks. For collecting data for cost-effectiveness analysis,
the participants will be followed up to 12 months from randomization.